Geode Capital Management LLC acquired a new stake in Autolus Therapeutics Ltd – (NASDAQ:AUTL) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 9,811 shares of the company’s stock, valued at approximately $322,000.
Separately, Virtus ETF Advisers LLC bought a new stake in shares of Autolus Therapeutics in the 4th quarter valued at approximately $312,000. Institutional investors and hedge funds own 40.63% of the company’s stock.
Several equities research analysts have recently issued reports on AUTL shares. William Blair reaffirmed a “buy” rating on shares of Autolus Therapeutics in a research note on Wednesday, April 3rd. HC Wainwright set a $45.00 price objective on Autolus Therapeutics and gave the company a “buy” rating in a research note on Wednesday, February 20th. Finally, Zacks Investment Research lowered Autolus Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, January 15th. One research analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $44.00.
NASDAQ:AUTL opened at $23.84 on Wednesday. The company has a market capitalization of $895.26 million and a PE ratio of -16.79. Autolus Therapeutics Ltd – has a 1 year low of $19.17 and a 1 year high of $53.24.
Autolus Therapeutics (NASDAQ:AUTL) last posted its quarterly earnings data on Tuesday, May 14th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.58) by ($0.11). On average, sell-side analysts predict that Autolus Therapeutics Ltd – will post -2.55 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Geode Capital Management LLC Invests $322,000 in Autolus Therapeutics Ltd – (AUTL)” was originally published by The Lincolnian Online and is owned by of The Lincolnian Online. If you are reading this article on another site, it was copied illegally and republished in violation of US and international copyright & trademark laws. The correct version of this article can be read at https://www.thelincolnianonline.com/2019/05/15/geode-capital-management-llc-invests-322000-in-autolus-therapeutics-ltd-autl.html.
Autolus Therapeutics Profile
Autolus Therapeutics plc, a biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company is developing AUTO1, a CD19-targeting programmed T cell therapy, which is in Phase I trial to reduce the risk of severe cytokine release syndrome; AUTO2, a dual-targeting programmed T cell therapy that is in Phase I/II clinical trial for the treatment of relapsed or refractory multiple myeloma; and AUTO3, a dual-targeting programmed T cell therapy, which is in Phase I/II clinical trials for treating relapsed or refractory diffuse large B-cell lymphoma.
Further Reading: What is Blockchain?
Want to see what other hedge funds are holding AUTL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Autolus Therapeutics Ltd – (NASDAQ:AUTL).
Receive News & Ratings for Autolus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autolus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.